Our 34 posters addressed critical themes including patient access strategies, holistic patient and caregiver value, evolving evidence frameworks, and the application of real-world evidence (RWE). Investigating such topics, our posters showcase the breadth of our expertise at Avalere Health and offer insights for value-based healthcare improvements.

In our panel session, “Go Broad: The Application of Indirect Burden of Disease Evidence in US Value Assessment and Ex-US HTA Submissions,” we explored the critical role of capturing indirect costs—such as productivity losses, caregiver impacts, and societal effects—in providing a holistic understanding of disease burden. With over 300 million people worldwide affected by rare diseases, often enduring diagnostic delays of 3–5 years or more, the panel emphasized the importance of inclusive economic assessments. Discussions highlighted how costs for rare diseases can exceed those of chronic conditions, the need to account for caregiver and societal impacts, and the varying approaches of global HTA agencies like PBAC, JCA, and NICE. The consensus? It’s time to prioritize measuring and presenting indirect costs to drive equitable, patient-centred healthcare decisions.

Together, our contributions at ISPOR Europe 2024 demonstrated the importance of integrating innovative methodologies and patient-focused insights into global healthcare systems, advancing outcomes for all stakeholders.